Shattuck Labs, Inc.
No SEC Form 4 filings for $STTK in the last 30 days.
Shattuck Labs, Inc.'s Chief Technical Officer, Abhinav A. Shukla, reported routine equity transactions. He exercised 5,122 warrants and received a grant of 5,122 common shares, increasing his direct holdings to 86,380 shares. These transactions stemmed from a private placement involving common stock and accompanying warrants issued under a securities purchase agreement in August 2025.
This article analyzes the valuation of Shattuck Labs Inc (STTK) based on various financial metrics. It indicates that STTK is currently in the "Fair zone" when compared to its five-year average forward PS ratio, noting a fair price range between NaN and NaN. The analysis also highlights STTK's Price-to-Book (P/B) ratio and Forward Free Cash Flow (FCF) yield, comparing them to historical averages and industry benchmarks.
Piper Sandler has initiated coverage on Shattuck Labs (STTK) with an "Overweight" rating and a price target of $15.00 USD, a significant increase from previous analyst targets. This new rating suggests a positive outlook for the biotechnology company, which specializes in developing treatments for inflammatory and immune-mediated diseases. While Wall Street analysts have an average target price of $7.25 for STTK, GuruFocus estimates a one-year GF Value of $0.55, indicating a potential downside.
